Assenagon Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $68.5M | Buy |
233,227
+85,393
| +58% | +$24.2M | 0.09% | 180 |
|
|
2026
Q1 | $41.2M | Buy |
147,834
+145,623
| +6,586% | +$41.9M | 0.06% | 229 |
|
|
2025
Q4 | $670K | Buy |
2,211
+415
| +23% | +$129K | ﹤0.01% | 1019 |
|
|
2025
Q3 | $504K | Sell |
1,796
-263
| -13% | -$71.6K | ﹤0.01% | 1051 |
|
|
2025
Q2 | $497K | Sell |
2,059
-2,366
| -53% | -$559K | ﹤0.01% | 1032 |
|
|
2025
Q1 | $1.08M | Buy |
+4,425
| New | +$1.33M | ﹤0.01% | 882 |
|
|
2024
Q4 | – | Sell |
-41,960
| Closed | -$14M | – | 1337 |
|
|
2024
Q3 | $14M | Sell |
41,960
-12,372
| -23% | -$3.93M | 0.03% | 439 |
|
|
2024
Q2 | $14.8M | Buy |
54,332
+14,457
| +36% | +$4.2M | 0.03% | 348 |
|
|
2024
Q1 | $13.8M | Buy |
39,875
+27,270
| +216% | +$8.97M | 0.03% | 354 |
|
|
2023
Q4 | $4.07M | Buy |
12,605
+6,429
| +104% | +$2.02M | 0.01% | 695 |
|
|
2023
Q3 | $2.21M | Buy |
6,176
+4,306
| +230% | +$1.66M | 0.01% | 820 |
|
|
2023
Q2 | $709K | Sell |
1,870
-177
| -9% | -$72K | ﹤0.01% | 1055 |
|
|
2023
Q1 | $981K | Sell |
2,047
-98,544
| -98% | -$46.1M | ﹤0.01% | 1052 |
|
|
2022
Q4 | $42.3M | Buy |
100,591
+88,853
| +757% | +$35.9M | 0.15% | 134 |
|
|
2022
Q3 | $4.9M | Hold |
11,738
| – | – | 0.02% | 494 |
|
|
2022
Q2 | $5.81M | Sell |
11,738
-10,021
| -46% | -$5.22M | 0.02% | 501 |
|
|
2022
Q1 | $12.3M | Buy |
21,759
+7,791
| +56% | +$4.7M | 0.03% | 316 |
|
|
2021
Q4 | $10.6M | Sell |
13,968
-3,431
| -20% | -$2.57M | 0.03% | 322 |
|
|
2021
Q3 | $13M | Buy |
17,399
+16,302
| +1,486% | +$12.2M | 0.04% | 258 |
|
|
2021
Q2 | $707K | Sell |
1,097
-28,273
| -96% | -$17.2M | ﹤0.01% | 974 |
|
|
2021
Q1 | $16.8M | Sell |
29,370
-69,186
| -70% | -$41M | 0.07% | 239 |
|
|
2020
Q4 | $57.5M | Buy |
98,556
+95,813
| +3,493% | +$54.6M | 0.25% | 78 |
|
|
2020
Q3 | $1.41M | Sell |
2,743
-151,825
| -98% | -$76.9M | 0.01% | 674 |
|
|
2020
Q2 | $69.8M | Buy |
154,568
+87,733
| +131% | +$38.7M | 0.45% | 39 |
|
|
2020
Q1 | $23.4M | Buy |
+66,835
| New | +$24.6M | 0.19% | 92 |
|
|
2019
Q3 | – | Sell |
-91,268
| Closed | -$28.5M | – | 856 |
|
|
2019
Q2 | $28.5M | Buy |
91,268
+25,065
| +38% | +$7.51M | 0.21% | 84 |
|
|
2019
Q1 | $20.2M | Buy |
66,203
+43,964
| +198% | +$11.9M | 0.19% | 104 |
|
|
2018
Q4 | $5.16M | Sell |
22,239
-96,258
| -81% | -$25.8M | 0.06% | 231 |
|
|
2018
Q3 | $37.1M | Sell |
118,497
-7,498
| -6% | -$2.33M | 0.37% | 63 |
|
|
2018
Q2 | $36.4M | Sell |
125,995
-2,971
| -2% | -$820K | 0.42% | 66 |
|
|
2018
Q1 | $32.3M | Buy |
128,966
+120,999
| +1,519% | +$30.8M | 0.42% | 65 |
|
|
2017
Q4 | $1.9M | Buy |
+7,967
| New | +$1.93M | 0.02% | 447 |
|
|
2017
Q3 | – | Sell |
-66,086
| Closed | -$15M | – | 460 |
|
|
2017
Q2 | $15M | Buy |
+66,086
| New | +$14.4M | 0.32% | 53 |
|
|
2017
Q1 | – | Sell |
-100,700
| Closed | -$18.4M | – | 265 |
|
|
2016
Q4 | $18.4M | Buy |
+100,700
| New | +$17.2M | 0.34% | 75 |
|
Other funds holding BIO
AI
Assenagon Asset Management's BIO Position: Q2 2026 in Review
Assenagon Asset Management increased its Bio-Rad Laboratories Class A (BIO) stake by 58% in Q2 2026, buying an estimated $24.2M and bringing the position to 233,227 shares worth $68.5M. The position accounts for 0.09% of the portfolio, ranked #180.
Assenagon Asset Management first reported a position in BIO in Q4 2016 and has held it in 34 quarters since. The position peaked at $69.8M in Q2 2020. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Assenagon Asset Management held 233,227 shares of Bio-Rad Laboratories Class A worth $68.5M as of Q2 2026.
- Assenagon Asset Management bought 85,393 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $24.2M.
- Bio-Rad Laboratories Class A made up 0.09% of Assenagon Asset Management's portfolio in Q2 2026, its #180 holding.
- Assenagon Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 34 quarters since.
- Assenagon Asset Management's Bio-Rad Laboratories Class A position peaked at $69.8M in Q2 2020.
- 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.